Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

20161,553 citationsJournal Article

Authors

Howard I. Scher · Cornell University

Michael J. Morris · Cornell University

Walter M. Stadler · Cornell University

Celestia S. Higano · Cornell University

Ethan Basch · Cornell University

Karim Fizazi · Cornell University

Emmanuel S. Antonarakis ·

Abstract

PCWG3 moves drug development closer to unmet needs in clinical practice by focusing on disease manifestations most likely to affect prognosis adversely for therapeutics tested in both nonmetastatic and metastatic CRPC populations. Consultation with regulatory authorities is recommended if a trial is intended to seek support for drug approval.

Topics & Keywords

Prostate Cancer Treatment and Research Cancer, Lipids, and Metabolism Prostate Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Journal of Clinical Oncology

Volume 34, Issue 12, pp. 1402-1418

DOI: 10.1200/jco.2015.64.2702

Field-Weighted Citation Impact: 94.74